DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to …

The ATTUNE S+™ Technology is yet another way that DePuy Synthes is driving evidence-based innovation intended to make continuous enhancements with the goal of positively affecting patient …

At DePuy Synthes, we see the person beyond the procedure. That's why we've built one of the most comprehensive orthopaedic portfolios in the world. Our innovations – across joint reconstruction, …

DePuy Synthes (/ dəˈpjuː /) is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson MedTech business …

Dec 20, 2022 · Discover how DePuy Synthes is advancing surgical care. See Johnson & Johnson's medical devices for joint repair, spine surgery & trauma treatment.

DePuy Synthes | 22,270 followers on LinkedIn. Humanly moved. | At DePuy Synthes, we see the person beyond the procedure. That’s why we’ve built one of the most comprehensive orthopaedic ...

Oct 14, 2025 · Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone …

The potential sale of DePuy Synthes would represent a defining moment for the orthopedic sector. While strategic buyers such as Zimmer Biomet or others may look logical on the surface, the combination …

Feb 20, 2026 · Bloomberg reports that Johnson & Johnson (NYSE: JNJ) aims to sell its DePuy Synthes Orthopaedics business for more than $20 billion.

May 28, 2026 · Analysis of J&J's DePuy Synthes separation and potential $20B+ sale, covering the 2025-2027 timeline, orthopedics revenue, VELYS robotics, buyer options, and medtech divestiture …